Charles Wood is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4950 Essen Lane
Baton Rouge, LA 708093482
Telephone
225-767-0847Registry record last updated 6 Apr 2017.
Clinical trials
- Greenlight Plus Study: Approaches to Early Childhood Obesity Prevention
Sponsor: Vanderbilt University Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20241 payment
- Novartis Pharmaceuticals CorporationProgram year20241 payment
- Daiichi Sankyo Inc.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
52.1%alpha-Adrenergic Blocker45.8%Tamsulosin Hcl100%Part D≥88 patientsCholinergic Muscarinic Antagonist6.2%Oxybutynin Chloride Er100%Part D≥16 patientsRespiratory
26.1%Corticosteroid14.3%Mometasone Furoate100%Part D≥44 patientsOpioid Agonist11.8%Hydrocodone-Acetaminophen100%Part D≥46 patientsNervous system
10.3%Benzodiazepine5.7%Alprazolam100%Part D≥34 patientsN-methyl-D-aspartate Receptor Antagonist2.8%Memantine Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
10 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Exploring the anti-inflammatory effects of cannabis on Alzheimer's disease associated neuropathology HIV infection and aging: An Autopsy Study
Lsu Health Sciences Center
FY2026$748,679R01AG099763 - AIDS Malignancies Training and Research International Program (AMTRIP)
Lsu Health Sciences Center
FY2026$34,056D43TW010354 - Kaposi Sarcoma in the Era of ART in Africa Program (KEAAP)
Lsu Health Sciences Center
FY2025$390,617U54CA277846
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”